MiNK Therapeutics, Inc.

INKT · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
70
SEC Filings

Business Summary

Competition. Some of our competitors have initiated clinical trials for GvHD, solid tumors and multiple myeloma, settings in which our iNKT cell therapy platform is currently being investigated. We are also aware of competitors pursuing cell therapy drug candidates, including but not limited to stem cell-based approaches, for the treatment of ARDS secondary to COVID-19. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies th...

Next Earnings

Q2 FY2026 — expected 2026-09-17

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionINKTdiscussed_in_filing Cybersecurity
topic_mentionINKTdiscussed_in_filing Cybersecurity
topic_mentionINKTdiscussed_in_filing Platform & Ecosystem
topic_mentionINKTdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001193125-26-134813EDGAR74K words
2025-03-182024-12-310000950170-25-041379EDGAR—
2024-03-212023-12-310000950170-24-034672EDGAR—
2023-03-242022-12-310000950170-23-009762EDGAR—
2022-03-182021-12-310001564590-22-011026EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001193125-25-282905EDGAR16K words
2025-08-142025-06-300000950170-25-108894EDGAR—
2025-05-152025-03-310000950170-25-072789EDGAR—
2024-11-142024-09-300000950170-24-127033EDGAR—
2024-08-132024-06-300000950170-24-096142EDGAR—
2024-05-142024-03-310000950170-24-059081EDGAR—
2023-11-142023-09-300000950170-23-063851EDGAR—
2023-08-102023-06-300000950170-23-040958EDGAR—
2023-05-112023-03-310000950170-23-021191EDGAR—
2022-11-032022-09-300000950170-22-021565EDGAR—
2022-08-152022-06-300001564590-22-029503EDGAR—
2022-05-132022-03-310001564590-22-020146EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-310001193125-26-133346EDGAR1K words
2026-03-270001193125-26-127931EDGAR—
2026-03-190001193125-26-116219EDGAR—
2026-01-020001193125-26-000916EDGAR—
2025-12-080001193125-25-311229EDGAR—
2025-09-290001193125-25-221863EDGAR—
2025-08-140001171843-25-005405EDGAR—
2025-07-150001193125-25-159017EDGAR—
2025-07-140000950170-25-095460EDGAR—
2025-06-180000950170-25-087888EDGAR—

70 total filings indexed. 43 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001840229
TickerINKT
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a4709f8ccc99cf985f4f0fdf6d95a1290237aaf1e0485af6d53a00f273b8f0e3
parent: 75f1c702a432892a9cf17be7927218e576aaebe2e4822b76fd0975a4821ad50c
content hash: 759132cb5ab232937040ac44fecbe455e503fa970f7d3d88e3e4061d2a26c5e5
signed: 2026-04-13T04:45:42.044Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf